Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Return on Invested Capital (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Return on Invested Capital for 4 consecutive years, with 0.5% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Invested Capital fell 8.0% to 0.5% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.5%, a 8.0% decrease, with the full-year FY2024 number at 0.55%, down 3.0% from a year prior.
  • Return on Invested Capital was 0.5% for Q3 2025 at Centessa Pharmaceuticals, down from 0.44% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.4% in Q1 2025 to a low of 0.66% in Q1 2023.
  • A 4-year average of 0.53% and a median of 0.57% in 2023 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 20bps in 2025; the steepest drop was -8bps in 2025.
  • Centessa Pharmaceuticals' Return on Invested Capital stood at 0.6% in 2022, then grew by 1bps to 0.59% in 2023, then skyrocketed by 32bps to 0.4% in 2024, then dropped by -24bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Return on Invested Capital are 0.5% (Q3 2025), 0.44% (Q2 2025), and 0.4% (Q1 2025).